The US Food and Drug Administration (FDA) has accepted Genentech's filing for Tecentriq (atezolizumab) as a treatment for colon cancer. This decision brings the UK one step closer to having access to this new treatment option. According to the FDA, Tecentriq is an immunotherapy drug that works by unleashing the body's immune system to fight cancer cells. The filing is based on clinical trials that showed Tecentriq improved survival rates in patients with colon cancer.
Colon cancer is the second most common type of cancer in the UK, with over 42,000 new cases diagnosed each year. The National Institute for Health and Care Excellence (NICE) recommends that patients with metastatic colorectal cancer should be offered immunotherapy as a treatment option, but the availability of specific treatments can vary depending on the individual patient's situation and the NHS trust they are being treated at.
The NHS has been working to improve the treatment options for patients with colon cancer, and this new development could bring a welcome boost. 'We are constantly looking for new and innovative treatments to improve patient outcomes,' said a spokesperson for the NHS. 'We will be keeping a close eye on developments in this area.'
While the FDA's decision is a positive step forward, it is not yet clear when or if Tecentriq will be made available to UK patients. This will depend on several factors, including the outcome of further clinical trials and the results of NICE's review of the treatment.
In the meantime, UK patients with colon cancer should continue to follow the recommended treatment guidelines, which include surgery, chemotherapy, and other targeted therapies. Patients with concerns about their treatment or those who are looking for the latest information on colon cancer should speak to their GP or contact NHS 111.